Pfizer

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Pfizer sits in the top decile of US sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count).

1,845 total trials 106 currently recruiting 1335 completed early-phase tilt top decile by trial count

Pfizer: 1,845 sponsored US clinical trials, 106 recruiting.

Pfizer sponsors 1,845 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 1,335 completed. 504 of these trials are in Phase 3-4 (later-stage) and 1,173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 44 trials.

Top-decile sponsor footprint

Pfizer ranks in the top decile of sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 39/100

1,335 of 1,673 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,845 total, page 6 of 37

TERMINATED Phase 1

Study of GBT021601 in Participants With Renal Impairment

NCT05878704

COMPLETED Phase 1

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

NCT05900154

COMPLETED Phase 1

A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.

NCT05884554

COMPLETED Phase 1

A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults

NCT05930925

COMPLETED Phase 1

A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.

NCT05857644

COMPLETED Phase 2

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

NCT05886777

COMPLETED Phase 1

A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults

NCT05890105

COMPLETED

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

NCT05932290

COMPLETED Phase 2

A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized

NCT05799495

COMPLETED Phase 1

A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.

NCT05878522

COMPLETED Phase 3

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease

NCT05842967

COMPLETED

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

NCT05858450

COMPLETED

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

NCT05873751

COMPLETED Phase 1

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults

NCT05831124

COMPLETED Phase 1

Voxelotor CYP and Transporter Cocktail Interaction Study

NCT05981365

COMPLETED Phase 1

A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.

NCT05822440

COMPLETED Phase 1

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults

NCT05807490

TERMINATED Phase 1

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

NCT05788328

COMPLETED

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

NCT05794191

COMPLETED Phase 1

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

NCT05767905

TERMINATED Phase 3

A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.

NCT05689164

COMPLETED

Treatment Patterns Among Patients With Venous Thromboembolism in the United States

NCT05795062

COMPLETED

A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis

NCT05139680

COMPLETED Phase 1

A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age

NCT05650333

COMPLETED Phase 1

A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults

NCT05745701

TERMINATED Phase 1

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

NCT05703607

TERMINATED Phase 1

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

NCT05671653

COMPLETED Phase 1

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

NCT05677867

TERMINATED Phase 2

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

NCT05732454

TERMINATED Phase 2

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

NCT05632354

COMPLETED Phase 3

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

NCT05634811

COMPLETED Phase 1

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

NCT05652660

COMPLETED Phase 3

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

NCT05583526

COMPLETED Phase 2

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

NCT05546476

COMPLETED

This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry

NCT05375942

COMPLETED Phase 4

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

NCT05518123

TERMINATED Phase 1

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

NCT05549323

TERMINATED Phase 2

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

NCT05579977

COMPLETED Phase 2

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

NCT05567952

COMPLETED

A Study to Learn About Recifercept in Patients With Achondroplasia

NCT05659719

COMPLETED Phase 4

Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

NCT05509400

COMPLETED Phase 1

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People

NCT05536440

COMPLETED Phase 1

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

NCT05654181

COMPLETED Phase 1

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

NCT05580003

TERMINATED

Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).

NCT05534789

COMPLETED

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

NCT05565391

COMPLETED Phase 2

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

NCT05375955

TERMINATED Phase 2

A Study of Ponsegromab in People With Heart Failure

NCT05492500

COMPLETED Phase 3

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

NCT05540522

TERMINATED Phase 1

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040

← Previous Page 6 of 37 Next →

Phase Distribution

PhaseTrial count
Phase 1 703
Phase 2 470
Phase 3 411
Phase 4 93

What is open in the Pfizer pipeline

106 recruiting of 1,845 indexed (6% open); 1,335 completed (72%).

Phase mix: 504 late (III/IV) vs 1,173 early (I/II) (early-phase heavy).

Top condition: Healthy (44 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Pfizer: open-pipeline peers nationwide

Peers matched on 1,845 registered trials and 6% open enrollment, not the therapeutic-area sidebar.

Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share PfizerMemorial Sloan Kettering Cancer CenterStanford UniversityDuke UniversityUniversity of California, San FranciscoPacira PharmaceuticalsBioDelivery Sciences InternationalColgate PalmoliveDurham VA Medical Center
Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,845 trials (± recruiting share)

Sponsors near 6% open enrollment (± trial volume)

What to do with this Pfizer page

1,845 registered trials is a research-attention snapshot, not an endorsement of Pfizer or any single study.

  • 106 of Pfizer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Pfizer pipeline card: 1,845 registered trials from official public datasets.Report a data error.